Marshall Urist

“We've always kind of existed in a competitive environment. I think there are other people who are doing this. It's a smaller group. There's no question. But, you know, I don't think we're super focused on competition right now in this space.”

“I want to focus today on our recent royalty deal for Chloramatug, which is our second investment in TTR amyloidosis. Beginning on slide 9, we recently acquired a portion of Neuromu's royalty interest in AstraZeneca's Chloramatug for up to $425 million.”

“So great to be here, Doug, and thanks to you and RBC for having us. So the first part of your question was sort of on the outlook for royalty financing. And, you know, we are really excited about where things stand today.”

“Certainly that there's just sort of a, they need to do more quicker. And so you need to be able to pull in a lot of resources to do that.”

“I actually want to start though with an announcement you made recently vis-a-vis your ambitions in China and Asia more broadly you hired a head of Asia it seemed like an impressive hire and quite the coup maybe you could tell us a little bit about the new head of Asia and your ambitions in that region yeah sure um so…”